Compare Amgen, Inc. (AMGN) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Goodyear Tire & Rubber Co — how do they compare? Amgen, Inc. trades at $415.69 (market cap $224.14B), while Goodyear Tire & Rubber Co trades at $5.95 (market cap $1.75B). The key difference: Amgen, Inc. is far larger — about 128.1× Goodyear Tire & Rubber Co's market cap, and Amgen, Inc. pays a 2.43% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| AMGN | GT | |
|---|---|---|
Market Cap | $224.14B | $1.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $10.54 |
52-Week Low | $271.18 | $5.58 |
Enterprise Value | $267.45B | $9.11B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Goodyear Tire & Rubber (GT) trades at $6.03, down 6.37% over 24 hours, reflecting bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -14.37% and ROE of -63.93% as of 2025, while recent Q2 2026 earnings missed on EPS but beat revenue estimates. Cash flow improved to a net $46 million in 2025, yet debt levels remain elevated with a debt-to-asset ratio of 34.36%.
Outlook remains challenging due to volume pressures and high costs, though analyst consensus leans hold (50%) with some buy support (34.62%). Key risks include sustained losses, competitive pressures, and macroeconomic headwinds impacting tire demand, requiring careful monitoring of turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
